Journal of Medical Economics
Volume 23, 2020 - Issue 6
Open access
1,968
Views
1
CrossRef citations to date
0
Altmetric
Rheumatology
A budget impact analysis for making treatment decisions based on anti-cyclic citrullinated peptide (anti-CCP) testing in rheumatoid arthritis
Sang Hee ParkPharmerit North America LLC – Modeling and Meta-Analysis, Bethesda, MD, USA;
, Xue HanBristol-Myers Squibb Co – US Health Economics and Outcomes Research, Lawrence Township, NJ, USACorrespondence[email protected]
, Francis LoboBristol-Myers Squibb Co – US Health Economics and Outcomes Research, Lawrence Township, NJ, USA
, David KratochvilPharmerit North America LLC – Modeling and Meta-Analysis, Bethesda, MD, USA;
& Dipen PatelPharmerit North America LLC – Modeling and Meta-Analysis, Bethesda, MD, USA;
Pages 624-630
|
Received 13 Jan 2020, Accepted 17 Feb 2020, Published online: 19 May 2020
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.